Despite 'lackluster' 2022, PwC remains 'bullish' on pharma M&A in 2023
While 2022 was shaping up to be a busy year for M&A, PwC recorded an overall “lackluster” amount of activity, with both deal size and volume down from last year. However, the accounting firm predicts a 2023 rebound.
In its latest deals outlook report, PwC predicted a more active 2023, with “M&A to more closely resemble prior years with a total deal value in the $225 billion to $275 billion range across all subsectors.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
